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Abstract 55 
Background: Endocrine therapies are the mainstay of treatment for estrogen-(E)-56 
receptor positive (ER+) breast cancer (BC). However, resistance remains problematic 57 
largely due to enhanced cross-talk between ER and growth-factor pathways, 58 
circumventing the need for steroid-hormones. Previously, we reported the 59 
antiproliferative effect of everolimus (RAD001-mTORC1 inhibitor) with endocrine 60 
therapy in resistance models however, potential routes of escape from treatment via 61 
ERBB2/3 signalling were observed. We hypothesised combined targeting of three 62 
cellular nodes: ER, ERBB and mTORC1 may provide enhanced long-term clinical 63 
utility. 64 
Methods: A panel of ER+ BC cell lines adapted to E-deprivation (LTED) and 65 
expressing ESR1
wt
 or ESR1
Y537S
, modelling acquired resistance to an aromatase-66 
inhibitor (AI), were treated in-vitro with a combination of RAD001 and neratinib 67 
(pan-ERBB inhibitor) in the presence or absence of estradiol (E2), tamoxifen (4-OHT) 68 
or fulvestrant (ICI182780). End points included proliferation, cell signalling, cell cycle 69 
and effect on ER-mediated transactivation. An in-vivo model of AI-resistance was 70 
treated with monotherapies and combinations to assess the efficacy in delaying tumour 71 
progression. RNA-seq analysis was performed to identify changes in global gene 72 
expression as a result of the indicated therapies. 73 
Results: Here, we show RAD001 and neratinib (pan-ERBB inhibitor) caused a 74 
concentration-dependent decrease in proliferation, irrespective of the ESR1 mutation 75 
status. Combination of either agent with endocrine therapy further reduced 76 
proliferation but the maximum effect was observed with a triple combination of 77 
RAD001, neratinib and endocrine therapy. In the absence of E, RAD001 caused a 78 
reduction in ER-mediated transcription in the majority of the cell lines, which 79 
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associated with a decrease in recruitment of ER to an E-response element on the TFF1 80 
promoter. Contrastingly, neratinib increased both ER-mediated transactivation and ER 81 
recruitment, an effect reduced by addition of RAD001. In-vivo analysis of an LTED 82 
model showed the triple combination of RAD001, neratinib and fulvestrant was most 83 
effective at reducing tumour volume. Gene-set-enrichment-analysis revealed addition 84 
of neratinib negated the EGF/EGFR feedback loops associated with RAD001.  85 
Conclusions: Our data supports the combination of therapies targeting ERBB2/3 and 86 
mTORC1 signalling together with fulvestrant in patients who relapse on endocrine 87 
therapy and retain a functional ER.  88 
 89 
Keywords: breast cancer, estrogen receptor, neratinib, everomilus, endocrine 90 
resistance. 91 
 92 
Background 93 
Breast cancer (BC) is the most common malignancy in women, responsible for over 94 
522,000 deaths in 2012 [1]. The majority of the BCs at primary diagnosis are estrogen 95 
receptor-alpha positive (ER+) and depend on estrogen (E) for their growth and 96 
progression. Endocrine therapies targeting estrogenic stimulation of tumour growth 97 
have been developed clinically and have shown success, reducing mortality of ER+ 98 
BC. These include tamoxifen, which competes with E for the ER; fulvestrant 99 
(ICI182780), which binds to ER and targets it for degradation; and aromatase 100 
inhibitors (AIs), which block the conversion of androgens to E [2]. Despite the initial 101 
effectiveness of these approaches, many patients eventually relapse with either 102 
intrinsic or acquired resistance and in most cases continue to express ER [3, 4]. 103 
Studies suggest that ESR1 mutations within the ligand binding domain of the receptor 104 
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and/or cross-talk between ER and various cellular kinases allow the receptor to 105 
circumvent the need for steroid hormone [5]. In recent years, emphasis has been 106 
placed on co-targeting both the ER and the phosphatidylinositol-3-kinase/protein 107 
kinase B/mammalian target of rapamycin (PI3K/AKT/mTORC) pathway, known to 108 
phosphorylate and activate ER in a ligand-independent manner [6], to avoid or reverse 109 
these resistance mechanisms. 110 
 111 
The combination of the rapalogue everolimus (RAD001) with exemestane, as third 112 
line therapy in ER+/ERBB2- negative patients who relapsed on prior endocrine 113 
therapy, was reported from the BOLERO-2 trial to increase median progression-free 114 
survival (PFS) from 4.1 to 10.6 months compared to exemestane alone [7]. 115 
Nonetheless, it is clear that blockade of a single protein in a complex signalling 116 
cascade, even if a critical downstream effecter, is unlikely to provide a total or 117 
prolonged growth inhibition partly as a result of early rewiring. For instance, a 118 
negative feedback-loop exists downstream in the PI3K/AKT/mTORC pathway such 119 
that mTORC1 inhibition leads to a reduction in S6K1 activity, which in turn allows 120 
IRS1/2 expression to be increased with associated enhanced activation of IGFR1-121 
dependent AKT activity [8]. Furthermore, mTORC1 blockade has also been shown to 122 
induce enhanced ERBB2/3 signalling [9], as well as ERK1/2 [8, 10], creating potential 123 
routes of escape negating the anti-tumour effectiveness of mTORC1 blockade and 124 
limiting long-term effectiveness (Fig. 1). This may account for the short-term clinical 125 
remissions and lack of stable disease, often with re-bound growth at the time of further 126 
disease progression. As such, it rational to explore targeting of the mTORC1 with 127 
vertical blockade of growth factor receptors, such as those governing ERBB signalling 128 
(Fig. 1).  129 
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 130 
In this study, we assessed the effect of the combined therapy of mTORC1 inhibitor, 131 
RAD001, with additional co-blockade of ERBB signalling with neratinib, an 132 
irreversible pan-ERBB receptor tyrosine kinase (RTK) inhibitor [11] [12] [13] in 133 
human BC cell models of endocrine sensitive and resistant disease with varying ESR1, 134 
PIK3CA and ERBB2 mutation status. Analysis showed that triple blockade of the three 135 
signalling nodes had greater efficacy than monotherapies both in-vitro and in-vivo and 136 
that the triple combination was well tolerated in xenograft model. 137 
 138 
Methods 139 
Reagents 140 
Primary antibodies against phospho-EGFR
tyr1068 
(CST-3777), total-EGFR (CST-2232), 141 
phospho-ERBB2
tyr1248 
(CST-2247), phospho-ERBB3
tyr1222 
(CST-4784), total-ERK1/2 142 
(CST-9102), phospho-AKT
ser473 
(CST-9271), total-AKT (CST-9272), phospho-143 
S6
ser240/244 
(CST-5364), total-S6 (CST-2217), phospho-ER
ser167 
(CST-5587), phospho-144 
Rb
ser807/811 
(CST-8516), CDK4 (CST-2901) and cyclinD1 (CST-2922) were purchased 145 
from Cell Signaling, Inc.; total-ERBB3 (sc-415), ER-alpha (sc-8002, F-10) and PARP 146 
(sc-8007) were purchased from Santa Cruz; phospho-ERK1/2 and -tubulin (T-9026) 147 
were obtained from Sigma and total-ERBB2 from Millipore. Secondary antibodies 148 
(anti-mouse and anti-rabbit horseradish peroxidase) were obtained from Dako. 17 -149 
estradiol (E2) and 4-hydroxytamoxifen (4-OHT) were purchased from sigma and 150 
fulvestrant (referred to as ICI) was obtained from Trocis, UK. Neratinib (PB272) was 151 
provided by Puma Biotechnology and Pfizer. Everolimus (RAD001) was purchased 152 
from Selleck. All chemicals, unless otherwise stated, were purchased from Sigma, UK. 153 
All tissue culture grade plastics were obtained from Nunc, UK. 154 
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 155 
Tissue Culture 156 
The human BC cell lines were obtained from the ATCC Rockville, USA or Asterand 157 
and authenticity was confirmed by STR. Cells were aliquoted to prevent phenotypic 158 
drift and routinely tested for Mycoplasma contamination. Wild-type (wt)-MCF7, wt-159 
HCC1428 and wt-SUM44 cell lines were cultured in phenol-red free RPMI medium 160 
supplemented with 10% fetal bovine serum (FBS) and 1nM E2. MCF7, HCC1428 and 161 
SUM44 cells adapted to long-term E deprivation (LTED) and modeling resistance to 162 
an AI were maintained in phenol-red free RPMI medium containing 10% dextran 163 
charcoal stripped serum (DCC) in the absence of E2 [14]. Cells were passaged twice 164 
weekly and fed every 48 to 72-hours. MCF7-LTED and HCC1428-LTED are 165 
homozygote for ESR1
wt
, whilst SUM44-LTED are heterozygote for ESR1
Y537S
. 166 
 167 
Cell proliferation assays 168 
Wt-MCF7, wt-SUM44, wt-HCC1428 and their LTED derivatives were seeded in 10% 169 
DCC medium into 96-well plates. Cell monolayers were left to acclimatize for 24-170 
hours before treatment with the drug combinations for 6-days with a treatment change 171 
on day-3. Cell viability was determined using the CellTiter-Glo® Luminescent Cell 172 
Viability Assay (Promega), according to the manufacture’s protocol.  173 
 174 
Transcription assays 175 
Cell lines were seeded in 24-well plates in DCC medium and left to acclimatize for 176 
24-hours. The following day transfection was performed using Fugene (Promega) with 177 
0.1g of E-response-element-linked-luciferase (EREIItkluc) and 0.1g of β-178 
galactosidase (pCH110) reporter constructs [15]. Luciferase (Promega) and β-179 
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galactosidase (GalactoStar, Applied Biosystems) activity were measured using a 180 
luminometer. 181 
 182 
Western Blotting 183 
Whole cell extracts were generated, as described previously [16]. Equal amounts of 184 
protein were resolved by SDS-PAGE and transferred to nitrocellulose membranes 185 
(Whatman). Antigen-antibody interactions were detected with Amersham ECL 186 
detection reagents (GE Healthcare). 187 
 188 
Chromatin Immunoprecipitation 189 
Wt-HCC1428 and HCC1428-LTED cells were cross-linked in 1% formaldehyde at 190 
room temperature for 10min and then quenched with 125mM glycine. Samples were 191 
then lysed, sonicated and chromatin was immunoprecipitated by overnight incubation 192 
at 4°C with ER (HC-20, sc-546) or IgG antibodies pre-bound with Protein G magnetic 193 
dynabeads (Invitrogen). Chromatin was washed vigorously with RIPA buffer and 194 
reversed cross-linked by an overnight incubation in elution buffer at 65°C. DNA was 195 
digested with RNase and Proteinase K, purified, precipitated with phenol chloroform 196 
and eluted in Tris-HCl pH8.0. Real-time qPCR was performed using TFF1 oligos 197 
forward: 5′ GGC CAT CTC TCA CTA TGA ATC ACT TCT GCA 3′ and reverse: 5′ 198 
GGC AGG CTC TGT TTG CTT AAA GAG CGT TAG 3′. 199 
 200 
Ion Torrent 201 
DNA was amplified using Ion AmpliSeq™ Library Kit 2.0 (Life Technologies), 202 
digested, Ion Xpress
TM 
Barcode adapters ligated and purified with Agencourt AMPure 203 
XP magnetic beads (Beckman Coulter). Libraries were quantified by qPCR using an 204 
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Ion Library Quantification Kit (Life Technologies), templated on the Ion OneTouch2 205 
System (Life Technologies) and sequenced on the Ion PGM System (Life 206 
Technologies). Reads were aligned by the PGM server with standard settings to the 207 
reference genome hg19, samtools v1.2 was used to calculate the on-target coverage. 208 
IonReporter
TM
 (v4.4) was used for mutation calling (parameters: Data Quality 209 
Stringency= 12, Downsample To Coverage= 4000, SNP/InDel/MNP Min Cov Each 210 
Strand= 50, SNP/InDel/MNP Min Variant Score= 15, SNP/InDel/MNP Min 211 
Coverage= 250, Hotspot Min Variant Score= 6, Hotspot Min Coverage= 150). All 212 
mutations called were manually reviewed in IGV and included in the analysis if they 213 
had a VAF ≥1%. 214 
 215 
Human tumour xenografts modelling relapse on AI therapy  216 
In-vivo studies were carried out in ovariectomized 8- to 12-week old female BALB/c 217 
FOX nude mice, in accordance with Home Office guidelines and approved by the 218 
Institute of Cancer Research Ethics Committee. MCF72a-LTED tumour xenografts 219 
were initiated by implantation of cells (10
7
) combined with matrigel (1:1) into the left 220 
flank. Tumours were established in the absence of E. Once tumours reached a diameter 221 
of 7-8mm, animals were assigned to treatment groups with no statistically significant 222 
differences in mean volume before treatment. Animals were treated with either vehicle, 223 
fulvestrant administrated subcutaneously weekly (5mg/Kg in olive oil), neratinib 224 
(40mg/Kg in 0.5% hydroxypropyl methylcellulose (HPMC)/0.4%Tween 80) or 225 
RAD001 (2mg/Kg in 0.5%HPMC/0.4%Tween80) administrated daily by oral gavage 226 
for a total of 41-days. Drugs were supplied alone or in the combinations indicated. 227 
Tumour growth was assessed weekly in all arms by caliper measurements of the two 228 
large diameters. Volumes were calculated according to the formula: a x b
2 
x /6, where 229 
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a and b are orthogonal tumour diameters. Tumour volumes were then expressed as 230 
mean fold-change in volume at the start of treatment. The study operator was blinded 231 
to the treatments.  232 
 233 
A second short-term study to address changes in gene expression was performed. 234 
Tumours from three mice per treatment were harvested 6-hours post-final drug 235 
administration following five full days of therapy. Tumours were snap frozen in liquid 236 
nitrogen for gene expression analysis.  237 
 238 
Immunohistochemical Analysis 239 
Tumour fragments were formalin fixed and parafin embedded. Sections were stained 240 
for ER using anti-ER antibody (6F11, Novocastra, UK) [17]  241 
 242 
RNA-seq 243 
Libraries were created after Ribo-zero rRNA removal kit (Illumina) using NEBNext 244 
Ultra Directional RNA (NEB) and sequenced using the HiSeq2500 (paired end 100bp 245 
v4 chemistry). Tophat (v2.1) and Cuffdiff (v2.2.1) [18] with default parameters were 246 
used for alignment and differential expression analysis.  Genes which have a fold 247 
change greater than 50% compared to vehicle in any condition were mapped to KEGG 248 
pathway graphs using Pathview [19]. Gene set enrichment analysis (GSEA) [20] was 249 
used to identify gene sets that were significantly up/down regulated in each treatment.  250 
[19]. The data supporting this study has been deposited in the NCBI gene expression 251 
omnibus (GSE112401). 252 
 253 
 254 
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Statistical Analysis 255 
Statistical analysis was performed using Student’s t-test or one-way ANOVA with 256 
Tukey’s to adjust for multiple comparisons. For xenograft studies, overall statistical 257 
differences were calculated using the Wilcoxon signed-rank test if the variance was 258 
not equal and failed the normality test, otherwise paired t-tests were used.  259 
 260 
Results 261 
Effect of RAD001 or neratinib alone or in combination with endocrine therapy on 262 
cell growth 263 
Endocrine sensitive and LTED BC cell lines retaining ER expression and with varying 264 
levels of EGFR, ERBB2, ERBB3 and FRAP1 expression [21] and differing PIK3CA, 265 
ERBB2 and ESR1 mutation status (Additional File S1: Figure S1a,b) were assessed 266 
for their sensitivity to escalating doses of RAD001 (Fig. 2a) or neratinib (Fig. 2b) in 267 
the presence or absence of E2. The addition of RAD001 to wt cell lines, in the absence 268 
of E2 showed minimal additional antiproliferative activity compared with E-269 
deprivation alone. Contrastingly, in the presence of E2, RAD001 caused a 270 
concentration-dependent decrease in proliferation of all wt cell lines tested. On the 271 
whole, even at the highest concentration of RAD001 (50nM), the antiproliferative 272 
effect was inferior to that seen with E-deprivation alone. Contrastingly, all LTED 273 
models showed a concentration dependent decrease in proliferation in the absence of 274 
E2 with varying degrees of sensitivity. Noteworthy, MCF7-LTED and SUM44-LTED, 275 
which harbour an ESR1
Y537S
 mutation, appeared most sensitive with IC50 values of 1.5 276 
and 0.5nM, respectively (Fig. 2a & Additional File S1: Figure S1c).  277 
 278 
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Escalating concentrations of neratinib caused a hormetic (bell shaped) proliferation 279 
curve in all wt cell lines tested in the absence of E2, with mid-range doses causing c. 280 
2-3 fold increase in proliferation. IC50 values for neratinib were not achieved in this 281 
setting (Fig. 2b and Additional File S1: Figure S1d). LTED derivatives in the 282 
absence of E2 showed IC50 values of 900nM for MCF7-LTED and SUM44-LTED and 283 
400nM for HCC1428-LTED. Addition of E2, increased the sensitivity of all wt cell 284 
lines with wt-MCF7 having the lowest recorded IC50 (300nM) (Fig. 2b and Additional 285 
File S1: Figure S1d). 286 
 287 
We subsequently assessed the interaction between RAD001 or neratinib with 288 
escalating doses of 4-OHT and ICI (Additional File S2: Figure S2 and Additional 289 
File S3: Figure S3). In the presence of exogenous E2, ICI and 4-OHT caused a 290 
concentration dependent decrease in proliferation in all wt and LTED cells. For all cell 291 
lines tested, RAD001 enhanced sensitivity to 4-OHT and ICI, with the exception of 292 
the HCC1428-LTED, in which no further antiproliferative effect was detected when 293 
RAD001 was combined with 4-OHT (Additional File S2: Figure S2,b). Similar 294 
responses were observed when neratinib was combined with the 4-OHT or ICI, with 295 
the exception of the wt-HCC1428 with ICI and HCC1428-LTED with 4-OHT, in 296 
which neratinib showed minimal impact, particularly at higher concentrations (>1nM) 297 
(Additional File S3: Figure S3a,b).   298 
 299 
Dual blockade of mTORC1 and ERBB signalling in combination with endocrine 300 
therapy enhances anti-proliferative effectiveness 301 
As altered growth factor signalling has been associated with mTORC1 blockade 302 
providing a route of resistance to long-term inhibition of this kinase [9], we examined 303 
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the strategy of combining RAD001 with neratinib in the presence of continued 304 
endocrine therapy. In order to assess this, suboptimal concentrations of each agent 305 
were combined in the presence or absence of E2. For all the cells lines tested, both in 306 
the presence and absence of E2, the combination of RAD001 and neratinib showed 307 
superior anti-proliferative effect compared to either agent alone (Fig. 3). 308 
 309 
In order to assess the effect of combining mTORC1 and ERBB suppression with 310 
endocrine therapy, cell lines were treated with sub-optimal concentrations of RAD001 311 
or neratinib alone or in combination, with escalating doses of 4-OHT or ICI. The 312 
combination of RAD001 and neratinib enhanced the efficacy of both endocrine agents, 313 
particularly at the lower concentration range (Additional File S4: Figure S4a,b).  314 
 315 
Effect of the combination of RAD001 and neratinib on cell signalling  316 
In order to investigate the effect of RAD001 and neratinib alone or in combination 317 
with endocrine agents on cellular signal transduction pathways, parental (endocrine 318 
sensitive) and LTED cell lines were treated with drug combinations indicated for 24-319 
hours ± E2, 4-OHT or ICI (Fig. 4). As expected, phosphorylation of S6 was 320 
dramatically suppressed by RAD001 alone or in combination with neratinib in all cell 321 
lines tested. Contrastingly, neratinib caused cell line specific effects on members of 322 
the ERBB family. For instance, neratinib caused a significant downregulation in total 323 
ERBB2 in all cell lines and reduced phosphorylated EGFR in MCF7-LTED, wt-324 
SUM44 and wt-HCC1428, as well as phosphorylated ERBB3 in wt-MCF7, wt-325 
SUM44 and HCC1428-LTED. Furthermore, RAD001, caused an upregulation of 326 
phosphorylated AKT in all cell lines tested and increased phosphorylation of ERK1/2 327 
in wt-SUM44, and to a lesser degree in SUM44-LTED, wt-HCC1428 and HCC1428-328 
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LTED, indicative of rapid re-wiring previously associated with resistance to mTORC1 329 
inhibition [8] [9] [10]. Noteworthy, in the majority of cell lines, the combination of 330 
RAD001 with neratinib suppressed the upregulation of phosphorylated AKT and 331 
ERK1/2 (Fig. 4).  332 
 333 
In order to investigate the impact of RAD001 or neratinib combined with 4-OHT or 334 
ICI versus the triple combination, on cell cycle progression, we assessed the 335 
abundance of pertinent cell cycle proteins. The combination of endocrine therapy with 336 
either RAD001 or neratinib decreased levels of phosphorylated RB, CyclinD1 and 337 
CDK4 to a greater extent than the endocrine therapies alone. However, as expected, 338 
the greatest degree of inhibition was evident with triple combination concomitantly 339 
blocking mTORC1, ERBB and ER-signalling, an effect most evident with ICI (Fig. 4). 340 
No substantial increase in cleaved-PARP was evident suggesting minimal impact on 341 
apoptosis. 342 
 343 
Effect of RAD001 alone or in combination with neratinib on ER-transactivation 344 
The majority of the patients who relapse on endocrine therapy retain expression of ER. 345 
In-vitro data has shown that ER can be phosphorylated in a ligand-independent 346 
manner, circumventing the need for steroid hormone. Major pathways associated with 347 
this include ERBB/ERK1/2 and PI3K/AKT/mTOR [6]. To assess whether interactions 348 
between the drugs impacted on E-independent transactivation, endocrine sensitive and 349 
LTED cell lines were transiently transfected with an ERE-luciferase reporter construct 350 
and treated with either RAD001, neratinib or the combination with or without E2, 4-351 
OHT or ICI (Fig. 5a and Additional File S5: Figure S5). Under E-deprived (DCC) 352 
conditions, mimicking the effects of an AI, neratinib caused a significant enhancement 353 
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in ER/ERE mediated transcription compared to the vehicle control in all cell lines 354 
tested (p 0.03) with the exception of SUM44-LTED, which showed a trend to 355 
significance (p=0.1). RAD001 alone suppressed ER-mediated transcription to varying 356 
extents across the cell lines. Most notably, wt-SUM44 and SUM44-LTED together 357 
with the HCC1428-LTED appeared most sensitive with a drop in ER-mediated 358 
transcription of approximately 50% compared to vehicle control. In contrast, wt-359 
MCF7 and their LTED derivatives, as well as wt-HCC1428 were unaffected. Of note, 360 
the combination of RAD001 and neratinib appeared to negate the neratinib driven 361 
increase in ER-mediated transcription in several of the models (p0.03). However, 362 
transactivation remained higher than that seen with RAD001 alone and indeed the 363 
combination did not reduce the effect of neratinib in wt-HCC1428 or MCF7-LTED.  364 
 365 
In order to address the enhanced ER/ERE-mediated transactivation in response to 366 
neratinib, chromatin immunoprecipitation was performed in wt-HCC1428 and 367 
HCC1428-LTED cells, which showed differential responses to neratinib when 368 
combined with RAD001 (Fig. 5a). ChIP analysis of ER recruitment in wt-HCC1428 369 
showed enrichment at the TFF1 promoter in response to neratinib compared to vehicle 370 
control. The combination of RAD001 and neratinib had no significant impact on 371 
recruitment, in keeping with the ER/ERE-mediated transcription analysis (Fig. 5a,b). 372 
Contrastingly, HCC1428-LTED showed enhanced recruitment of ER in response to 373 
neratinib, which was significantly reduced by the addition of RAD001 (p<0.001) (Fig. 374 
5b), suggesting context specific impacts on ER-mediated transcription were 375 
responsible for these events. 376 
 377 
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Suboptimal concentrations of 4-OHT or ICI caused between a 40-60% reduction in 378 
ER-transactivation in all cell lines, with the exception of HCC1428-LTED in response 379 
to 4-OHT where the reduction did not meet statistical significance. Similarly, SUM44-380 
LTED, which harbours a Y537S mutation in ESR1, showed no response to either 4-381 
OHT or ICI. The combination of RAD001 or neratinib with endocrine therapy showed 382 
no further reduction in ER-mediated transcription compared to endocrine therapy 383 
alone in all cell lines tested with the exception of the SUM44 models. In this setting, 384 
RAD001 in combination with 4-OHT or ICI caused a significant reduction in ER-385 
mediated transcription. However, the addition of neratinib showed no impact and 386 
indeed the triple combination impeded ER-mediated transactivation to a similar degree 387 
as RAD001 when combined with either endocrine agent. This suggests the wt-SUM44 388 
and SUM44-LTED are particularly sensitive to cross talk between ER and mTORC1 389 
signalling. Indeed, the combination of 4-OHT with RAD001 significantly reduced 390 
pER
ser167
 and total ER (Additional File S5: Figure S5). 391 
 392 
Effect of RAD001 alone or in combination with neratinib and/or fulvestrant in-393 
vivo 394 
To assess the effect of the drugs as monotherapies or combinations on tumour volume 395 
in-vivo, mice were implanted with MCF72a-LTED ER+ tumour cells, which grow 396 
independently of exogenous E and model relapse on an AI (details regarding 397 
generation of this model are shown in Additional File S6: Figure S6a). Animals were 398 
treated with vehicle, monotherapy (RAD001, neratinib or fulvestrant), dual or triple 399 
therapy combinations. The mean fold-change in tumour volume for each treatment 400 
was expressed relative to the start of treatment (Fig. 6a).  Tumour volumes for the 401 
control vehicle group increased 1.8 times over the treatment period (p=0.1). All 402 
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monotherapies caused a reduction in tumour volume by day 41 compared to the start 403 
of treatment  (RAD001: 36%, p=0.03; neratinib: 23%, p=0.6; fulvestrant: 37%, 404 
p=0.03). Dual combination therapies showed a further reduction in tumour volume 405 
(RAD001+neratinib: 73%, p=0.03; RAD001+fulvestrant: 72%, p=0.004; 406 
neratinib+fulvestrant: 65%, p=0.004). Triple combination of RAD001, neratinib plus 407 
fulvestrant was the most effective resulting in an 80% inhibition in tumour growth 408 
(p=0.008). Assessment of mouse weights showed the drug combinations had no 409 
significant effect during course of the study (Fig. 6b). 410 
 411 
In order to assess dynamic changes in gene expression in response to RAD001, 412 
neratinib or the combinations with fulvestrant, a second short-term xenograft study 413 
was carried out followed by RNA-seq. Differentially expressed genes were subjected 414 
to pathway analysis (Additional File S6: Figure S6b). As expected, RAD001 415 
increased AKT and ERK expression, which was reduced by the addition of neratinib. 416 
ER expression was elevated with neratinib treatment compared to RAD001 and 417 
fulvestrant. Noteworthy, CoR expression was elevated in the dual (RAD001 plus 418 
neratinib) and triple combination. Furthermore, global effects on proliferation showed 419 
a greater reduction with the dual and triple combinations compared to single agents. 420 
This was further supported by the assessment of E2F target genes (Additional File 421 
S6: Figure S6c). As expected, the triple combination of RAD001, neratinib and 422 
fulvestrant suppressed the expression of cell cycle associated genes (CCNE1, CCNL1, 423 
CDK3, CDK7 and CDK9) when compared with RAD001 alone or in combination with 424 
neratinib, in keeping with the longer-term xenograft study (Additional File S7: 425 
Figure S7a). Based on the pathway analysis, we used gene set enrichment analysis 426 
(GSEA) to assess the dynamic changes in EGFR/ERBB2 signalling after blockade 427 
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with neratinib, RAD001 or the combinations. Neratinib reduced expression of genes 428 
associated with EGF/EGFR activation of ERK signalling [22] (p=0.004) (Fig. 6c) 429 
contrastingly, RAD001 significantly induced expression of this gene set (p=0.03) (Fig. 430 
6d), an observation in support of rapid re-wiring associated with resistance to 431 
mTORC1 inhibition. As expected, the combination of neratinib and RAD001 432 
significantly reduced expression of the EGFR/ERK gene set (p=0.003) (Fig. 6e). 433 
Addition of fulvestrant to the double combination showed a further trend in the 434 
reduction of this (p=0.09) (Fig. 6f). Finally, assessment of the fulvestrant alone or in 435 
combination with RAD001 showed no impact on EGFR/EGF regulated genes, 436 
however the addition of neratinib significantly reduced the EGFR/ERK gene set 437 
(p<0.0001) (Additional File S7: Figure S7b). Taken together, this suggests that the 438 
addition of neratinib negates the EGF/EGFR feedback loop, providing further support 439 
for the antiproliferative effect seen with the triple combination, highlighting the 440 
potential utility of concomitantly targeting three cellular signalling nodes.  441 
 442 
Discussion  443 
In-vitro and in-vivo analysis of tumours that are resistant to endocrine therapy suggests 444 
complex interplay between cell signalling molecules, which cooperate to govern 445 
escape mechanisms. Treatment with small molecule inhibitors of pertinent pathways 446 
may provide clinical benefit. For instance, recent studies have shown that blockade of 447 
mTORC1 signalling in combination with AI therapy, causes a marked increase in PFS 448 
in patients with metastatic ER+ BC (BOLERO-2) [7], however, relapse remains a 449 
significant clinical issue.  450 
 451 
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In order to identify potential pathways attributed to lack of response to RAD001, we 452 
previously carried out a molecular study in cell lines adapted to LTED, modelling the 453 
patient cohort on the BOLERO-2 study. We showed that RAD001 induced a 454 
feedback-loop via ERBB2/3, which could potentiate resistance [9]. In further support, 455 
Carracedo and colleagues [10] showed a similar up-regulation of ERK1/2 in response 456 
to mTORC1 inhibition. Furthermore, studies using ERBB inhibitors have highlighted 457 
resistance pathways via up-regulation of PI3K/mTORC/AKT signalling [23] [24], 458 
suggesting a high degree of cross talk between these two pivotal cellular signal 459 
transduction pathways. In addition, both PI3K/mTORC/AKT and ERK1/2 have been 460 
implicated in the ligand-independent activation of ER, leading to resistance to 461 
endocrine therapy [6]. Based upon these observation, we hypothesised simultaneous 462 
blockade of all three cellular nodes may provide potential benefit circumventing the 463 
resistance seen with individual therapies. In order to test this, we assessed the 464 
combination of neratinib, a pan-ERBB inhibitor, with the mTORC1 inhibitor, 465 
RAD001, in the presence of various endocrine agents in models mimicking endocrine 466 
sensitive and AI resistant disease. 467 
Surprisingly, treatment of endocrine sensitive BC cells with neratinib in the absence of 468 
exogenous E2 generated a hormetic response curve, with lower concentration of the 469 
drug causing a marked increase in proliferation and associated ER-mediated 470 
transactivation. Previous clinical studies have reported mixed benefit of the 471 
combination of AI with EGFR or ERBB2 blockade in primary or naïve advanced BC 472 
and in some cases have shown a trend towards poorer outcome [25] [26]. Furthermore, 473 
this observation is not only evident with targeted EGFR and ERBB2 RTKs but also 474 
with pan-ERBB inhibitors, such as AZD8931, in which, a recent phase II randomised 475 
study in combination with an AI in women with endocrine naïve advanced BC 476 
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provided no benefit compared to anastrozole alone and did not delay endocrine 477 
resistance in this patient population [27]. Noteworthy, treatment of LTED cell lines 478 
also showed enhanced ER/ERE-mediated transcription and recruitment of ER to target 479 
promoters in response to neratinib. However, in contrast to the parental cell lines, 480 
proliferation decreased. The decrease in proliferation is in keeping with clinical studies, 481 
which suggest that patients, who have acquired resistance to endocrine therapy via up-482 
regulation of EGFR/ERBB2, may benefit from pan-ERBB inhibition, as they become 483 
more reliant on growth factor signaling as the mitogenic driver [26]. 484 
 485 
In contrast to E-deprivation, the combination of neratinib with 4-OHT or ICI showed 486 
enhanced antiproliferative effect in the majority of parental cell lines. However, 487 
although the combination outperformed either treatment alone at the concentrations 488 
tested, the magnitude of benefit was less than would be expected from additive benefit 489 
from either treatment alone. These data are in keeping with previous in-vitro, as well 490 
as clinical studies, assessing the combination of EGFR blockade with gefitinib to 491 
delay the onset of endocrine resistance [28] [29]. The mechanism underlying this 492 
remains unclear, but in vitro studies suggest tamoxifen-bound-ER binds co-repressor 493 
molecules allowing the ERBB2 promoter to sequester SRC1 and AIB1 leading to 494 
transcription of ERBB2 potentially providing the target for RTK inhibition [30].  495 
 496 
Treatment with RAD001 showed differential effects on cell proliferation. Most 497 
notably, the LTED derivatives showed lower IC50 values compared to their parental 498 
cell lines with the exception of HCC1428. PIK3CA mutation status was not a 499 
governing factor of sensitivity, as both SUM44 and HCC1428 harbour the wt-gene. 500 
Wt-SUM44 in the absence of exogenous E2 showed no response to RAD001 however, 501 
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this was attributed to the fact that in E-deprived conditions, the majority of cells are in 502 
cell cycle arrest as such further perturbation provides little effect. This was confirmed 503 
by the observation in the presence of E2 where the IC50 was c. 3nM, similar to that 504 
seen in MCF7-LTED. These data again show that mutation status is not the governing 505 
feature of sensitivity and cellular context remains more informative and are in keeping 506 
with the translational study of BOLERO2, which showed that PIK3CA mutations were 507 
not in themselves predictive of clinical benefit to mTORC1 inhibitors [31]. Treatment 508 
with RAD001 decreased ER-mediated transcription, as a result of reduced S6 kinase 509 
activity, and subsequent phosphorylation of ER
ser167
, which was particularly notable in 510 
wt-SUM44 and their LTED derivative. Allosteric inhibition of mTORC1 led to an 511 
increase in phosphorylated AKT, indicative of the previously observed S6 feedback 512 
loop [8]. Furthermore, in certain cell lines ERK1/2 was also elevated. This may 513 
indicate that phospho-ERK activation following mTORC1 inhibition occurs via cross-514 
talk with the PI3K-RAS signalling pathway [10]. In selected cell lines, evidence 515 
suggested that enhanced ERBB signalling maybe responsible for the observed ERK 516 
activation. Indeed, GSEA analysis showed RAD001 increased expression of 517 
EGF/EGFR associated genes which was significantly suppressed by the addition of 518 
neratinib. In keeping, our in-vivo study showed concordant data in which the triple 519 
combination significantly reduced tumour volume. 520 
 521 
Taken together, these data support the combination of mTORC1 blockade with 522 
inhibition of ERBB signalling and ER-function in ER+ BC, highlighting the potential 523 
clinical utility. Further support for the dual blockade of both mTORC1 and ERBB 524 
signalling comes from a recent phase I clinical trial piloting the combination of 525 
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neratinib with temsirolimus, in which, antitumoral activity in patients with advanced 526 
BC was evident [32].  527 
 528 
Conclusions 529 
In conclusion, our results provide support for the combination of RAD001 together 530 
with neratinib and endocrine therapy to re-sensitise endocrine resistant tumours to the 531 
antiproliferative effects of endocrine therapy. Most notably, the combination with ICI, 532 
disabling both the ER and AKT axis appeared superior. Furthermore, even within this 533 
restricted panel of cell lines, the heterogeneity of response highlights the need to 534 
identify common adaptive nodes. 535 
 536 
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Figure Legends 719 
Figure 1. Simplified schematic diagram of the pathways described in this study. 720 
(a) Growth factor signalling (IGFR and ERBB) leads to activation of PI3K and 721 
phosphorylation of AKT. AKT inhibits TCS1/2 resulting in upregulation of mTORC1. 722 
In parallel, mTORC1 can also be upregulated by the RAS-RAF-MEK-ERK signalling 723 
pathway. ERK phosphorylates and inactivates TCS2 also leading to mTORC1 724 
activation. S6K1 activity increases as a result of mTORC1 activation. S6K1 725 
suppresses mTORC2 and IRS1. ER is also a target of S6K1 leading to phosphorylation 726 
of serine 167. (b) Inhibition of mTORC1 with everolimus suppresses S6K1 removing 727 
the negative feedback loop causing a rise in IRS1 and AKT activity via loss of 728 
suppression on mTORC2. Increased AKT activity suppresses TCS1/2 and increases 729 
expression of growth factor receptors (ERBB2/3) enhancing RAS-RAF-ERK 730 
signalling. (c) The dual blockade of ERBBs (neratinib) and mTORC1 signalling 731 
(everolimus) may suppress the two feedback loops described in panel B. Yellow 732 
shows normal mTORC signalling cascade; blue represent activated proteins; red 733 
represents inhibited proteins; dotted lines show loss of normal feedback loops. 734 
 735 
Figure 2. Antiproliferative effect of (a) RAD001 and (b) neratinib in endocrine 736 
resistant and sensitive BC cell lines. Cells were treated in absence or presence of 737 
exogenous E2 (0.01nM) and doubling concentrations of RAD001 or neratinib. 738 
Treatments were performed at day 1 and day 3 after seeding. After 6 days of treatment, 739 
cell viability was analyzed by using a cell titer-glo assay. Data are expressed as fold-740 
change relative to DCC control. Error bars represent mean ± SEM. 741 
 742 
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Figure 3. Antiproliferative effect of RAD001, neratinib or their combination in 743 
endocrine resistant and sensitive BC cell lines. Cell lines were treated with vehicle, 744 
suboptimal concentrations for each drug alone or in combination, both in the absence 745 
and presence of 0.01nM exogenous E2. After 6 days of treatment, cell viability was 746 
analysed using cell titer-glo and data expressed as fold-change relative to vehicle 747 
control. Error bars represent mean ± SEM. *p<0.05; **p<0.01; ***p<0.001.  748 
Concentrations used in DCC: wt-MCF7 (0.75nM RAD001; 2000nM neratinib); 749 
MCF7-LTED (0.75nM RAD001; 500nM neratinib); wt-SUM44 (0.75nM RAD001; 750 
2000nM neratinib); SUM44-LTED (0.4nM RAD001; 500nM neratinib); wt-HCC1428 751 
(12.5nM RAD001; 1200nM neratinib); HCC1428-LTED (3nM RAD001; 250nM 752 
neratinib). Concentrations used in E2: wt-MCF7 (1.5nM RAD001; 200nM neratinib); 753 
MCF7-LTED (1.5nM RAD001; 300nM neratinib); wt-SUM44 (0.37nM RAD001; 754 
450nM neratinib); SUM44-LTED (0.37nM RAD001; 250nM neratinib); wt-HCC1428 755 
(1.5nM RAD001; 500nM neratinib); HCC1428-LTED (3nM RAD001; 250nM 756 
neratinib) 757 
 758 
Figure 4. Effect of RAD001, neratinib or their combination with endocrine agents 759 
on cell signalling pathways governing cell cycle. Endocrine resistant and sensitive 760 
BC cell lines were treated for 24-hours with the drug combinations indicated. Whole-761 
cell extracts were assessed for expression on S6 kinase, ERK1/2, AKT and ERBB 762 
signalling together with markers of cell cycle and apoptosis by immunoblotting. IC50 763 
values were used for RAD001 and neratinib together with standard concentrations of 764 
E2 (0.01nM), 4-OHT (10nM) and ICI (1nM) (with exception of HCC1428-LTED, in 765 
which 10nM was used). ERBB pathways are highlighted in pink, ERK1/2 in blue, 766 
mTORC1/AKT in green and cell cycle in orange. 767 
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wt-MCF7 (2nM RAD001; 500nM neratinib); MCF7-LTED (4nM RAD001; 750nM 768 
neratinib); wt-SUM44 (3nM RAD001; 700nM neratinib); SUM44-LTED (3nM 769 
RAD001; 700nM neratinib); wt-HCC1428 (3nM RAD001; 1000nM neratinib); 770 
HCC1428-LTED (10nM RAD001; 500nM neratinib). 771 
 772 
Figure 5. Effect of RAD001, neratinib or their combination on ER-mediated 773 
transactivation and recruitment of the ER-basal transcription machinery. (a) Cell 774 
lines were co-transfected with EREIItkLuc and pCH110 and treated for 24-hours with 775 
RAD001 and neratinib in the absence of E2 (DCC). Luciferase activity was 776 
normalized by -galactosidase from triplicate wells and fold-changes expressed 777 
relative to the DCC control. (b) ChIP analysis to determine the effect of neratinib, 778 
RAD001 or the combination on recruitment of ER to the TFF1 promoter in wt-779 
HCC1428 and HCC1428-LTED. Error bars represent mean ± SEM. *p<0.05; 780 
**p<0.01; ***p<0.001.  781 
Concentration used for transactivation assay and ChIP: wt-MCF7 (2nM RAD001; 782 
500nM neratinib); MCF7-LTED (4nM RAD001; 650nM neratinib); wt-SUM44 (3nM 783 
RAD001; 700nM neratinib); SUM44-LTED (3nM RAD001; 700nM neratinib); wt-784 
HCC1428 (3nM RAD001; 700nM neratinib); HCC1428-LTED (10nM RAD001; 785 
300nM neratinib). 786 
 787 
Figure 6. Effect of the RAD001 and neratinib alone or in combination with 788 
endocrine therapy in-vivo.  (a) Long-term study assessing the relative mean changes 789 
in tumour volume over 41 days of treatment and (b) Effect of drug regimes on animal 790 
weight. Error bars represent mean ± SEM (n=7-9 animals per group). RAD, RAD001 791 
(2mg/Kg); Ner, neratinib (40mg/Kg); ICI, fulvestrant (5mg/Kg). (c-f) GSEA 792 
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enrichment plots for 198 genes known to be induced by sustained activation of ERK in 793 
response to EGF activity.  Plots show the profile of the running Enrichment Score and 794 
positions of GeneSet Members on the Rank Ordered List for rank gene lists generated 795 
from the comparison of (c) neratinib vs. vehicle; (d) RAD001 vs. vehicle; (e) RAD001 796 
+ neratinib vs. RAD001; (f) RAD001 + neratinib + ICI vs. RAD001 + neratinib.  797 
 798 
Additional Files 799 
Additional File S1: Figure S1. IC50 values for antiproliferative effect of RAD001 800 
and neratinib in relation to the ESR1, ERBB2 and PIK3CA mutational status in 801 
endocrine resistant and sensitive BC cell lines. (a) Mutational or wt status is 802 
depicted in grey and white, respectively, for ESR1, ERBB2 and PIK3CA. (b) Varying 803 
degrees of expression of genes encoding proteins targeted by fulvestrant, neratinib and 804 
RAD001 showing heterogeneity in the cell lines tested. (c-d) Cells were treated in 805 
absence or presence of exogenous estradiol (E2) (0.01nM) and doubling 806 
concentrations of (c) RAD001 or (d) neratinib. Treatments were performed at day 1 807 
and day 3 after seeding. After 6 days of treatment, cell viability was analyzed by using 808 
a cell titer-glo assay and IC50 values were plotted.  809 
 810 
Additional File S2: Figure S2. Antiproliferative effect of RAD001 in combination 811 
with endocrine agents (a) 4-OHT and (b) ICI. Endocrine resistant and sensitive BC 812 
cell lines were treated with a combination of RAD001 (3nM) and increasing 813 
concentrations of (a) 4-OHT or (b) ICI for 6 days with media change at day3. Cell 814 
viability was analyzed by using a cell titer-glo assay. Data are expressed as fold-815 
change relative to vehicle control. Error bars represent mean ± SEM. 816 
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Additional File S3: Figure S3. Antiproliferative effect of neratinib in combination 818 
with endocrine agents (a) 4-OHT and (b) ICI. Endocrine resistant and sensitive BC 819 
cell lines were treated with a combination of neratinib (500nM in wt-MCF7 and 820 
MCF7-LTED; 700nM in wt-SUM44, SUM44-LTED and wt-HCC1428; 300nM in 821 
HCC1428-LTED) and increasing concentrations of (a) 4-OHT or (b) ICI for 6 days 822 
with media change at day 3. Cell viability was analyzed by using a cell titer-glo assay. 823 
Data are expressed as fold-change relative to vehicle control. Error bars represent 824 
mean ± SEM. 825 
 826 
Additional File S4: Figure S4. Antiproliferative effect combination of RAD001 827 
and neratinib together with endocrine agents (a) 4-OHT and (b) ICI. Endocrine 828 
resistant and sensitive BC cell lines were treated with a combination of RAD001 and 829 
neratinib and increasing concentrations of (a) 4-OHT or (b) ICI for 6 days with media 830 
change at day 3. Cell viability was analyzed by using a cell titer-glo assay. Data are 831 
expressed as fold-change relative to vehicle control. Error bars represent mean ± SEM. 832 
wt-MCF7 (1.5nM RAD001; 200nM neratinib); MCF7-LTED (1.5nM RAD001; 833 
300nM neratinib); wt-SUM44 (0.37nM RAD001; 450nM neratinib); SUM44-LTED 834 
(0.37nM RAD001; 250nM neratinib); wt-HCC1428 (1.5nM RAD001; 500nM 835 
neratinib); HCC1428-LTED (3nM RAD001; 250nM neratinib). 836 
 837 
Additional File S5: Figure S5. Effect of RAD001, neratinib or their combination 838 
with endocrine agents on ER-mediated transactivation and ER signalling. Cell 839 
lines were co-transfected with EREIItkLuc and pCH110, and treated for 24-hours with 840 
the drug combinations indicated. IC50 values were used for RAD001 and neratinib 841 
together with standard concentrations of E2 (0.01nM), 4-OHT (0.1nM) and ICI 842 
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(0.1nM). Luciferase activity was normalized by -galactosidase from triplicate wells 843 
and fold-changes expressed relative to the E2 control. Error bars represent mean ± 844 
SEM. *p<0.05; **p<0.01; ***p<0.001. wt-MCF7 (2nM RAD001; 500nM neratinib); 845 
MCF7-LTED (4nM RAD001; 650nM neratinib); wt-SUM44 (3nM RAD001; 700nM 846 
neratinib); SUM44-LTED (3nM RAD001; 700nM neratinib); wt-HCC1428 (3nM 847 
RAD001; 700nM neratinib); HCC1428-LTED (10nM RAD001; 300nM neratinib). 848 
Western blot was used to assess changes in phosphorylation of the ER in response to 849 
RAD001, neratinib or their combination together with endocrine agents. IC50 values 850 
were used for RAD001 and neratinib together with standard concentrations of E2 851 
(0.01nM), 4-OHT (10nM) and ICI (1nM) (with exception of HCC1428-LTED, in 852 
which 10nM was used). wt-MCF7 (2nM RAD001; 500nM neratinib); MCF7-LTED 853 
(4nM RAD001; 750nM neratinib); wt-SUM44 (3nM RAD001; 700nM neratinib); 854 
SUM44-LTED (3nM RAD001; 700nM neratinib); wt-HCC1428 (3nM RAD001; 855 
1000nM neratinib); HCC1428-LTED (10nM RAD001; 500nM neratinib). 856 
 857 
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Additional File S6: Figure S6. Assessment of dynamic changes in gene expression 859 
in response to RAD001, neratinib or the combinations with fulvestrant. (a) 860 
MCF72a cells, which were previously engineered to express aromatase (CYP19) [33] 861 
were implanted into ovariectomised mice under androstenedione support. In this 862 
setting, MCF72a cells convert androstenedione in to estrogen to drive proliferation. 863 
Once tumours developed, androstenedione was withdrawn. After a lag phase tumour 864 
growth occurred synonymous with ligand-independence. Assessment of the MCF72a-865 
LTED showed continued expression of ER and proliferation in the absence of 866 
exogenous estrogen providing a model of AI-relapse. (b) Changes to gene expression 867 
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(log2 difference Drug – Vehicle) as detected by RNA-seq for five drug combinations 868 
(neratinib, RAD001, ICI, neratinib+RAD001 and neratinib+RAD001+ICI) were 869 
mapped to KEGG pathway graphs using Pathview 870 
(https://bioconductor.org/packages/release/bioc/html/pathview.html). Genes with a 871 
fold-change greater than 50% compared to vehicle in any condition were selected in 872 
order to expand the list of differentially expressed genes, allowing the identification of 873 
subtle changes in gene expression for example kinases or transcription factors that 874 
might have significant impact on downstream gene expression. A heatmap for each 875 
gene in shown. (c) Assessment of expression of E2F target genes in response to 876 
neratinib and RAD001. 877 
 878 
Additional File S7: Figure S7. Assessment of dynamic changes in expression of 879 
cell cycle regulatory genes. (a) Log2 differences in CCNE1, CCNL1, CDK3, CDK7 880 
and CDK9 gene expression following treatment with RAD001, RAD001 + neratinib 881 
and RAD001 + neratinib + fulvestrant (ICI), compared to vehicle. (b) GSEA 882 
enrichment plots for 198 genes known to be induced by sustained activation of ERK in 883 
response to EGF activity.  Plots show the profile of the running Enrichment Score and 884 
positions of GeneSet Members on the Rank Ordered List for rank gene lists generated 885 
from the comparison of ICI vs. vehicle; neratinib + ICI vs. ICI; RAD001 + ICI vs. ICI; 886 
RAD001 + neratinib + ICI vs. RAD001 + ICI. 887 
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